This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
This small volume presents in a simple and concise manner the value and technic of serum therapy in pneumonia. The immunologic and bacteriologic aspects of the disease are discussed in the light of recent developments. Both authors have been intimately connected with the study of pneumonia in Massachusetts. This experience has demonstrated beyond much doubt that concentrated antipneumococcus serum, if given early in the disease, will reduce the mortality inlobar pneumonia due to Pneumococcus types I and II by about 50 per cent.
It is pointed out that there are few data in regard to the use of serum in children. In 30 per cent of the cases of lobar pneumonia in patients under 12 years the condition is, however, due to Pneumococcus type I or type II and is therefore treatable. Routine use of serum is not advocated because of the low mortality rate in children, but in very
Lobar Pneumonia and Serum Therapy. Am J Dis Child. 1936;52(1):250. doi:10.1001/archpedi.1936.04140010259021
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.